O. Landgren et al.: Monoclonal gammopathy of undetermined significance (mgus) consistently precedes multiple myeloma: a prospective study. In: Blood. 113. Jahrgang, Nr.22, 2009, S.5412–5417, doi:10.1182/blood-2008-12-194241, PMID 19179464.
H. T. Tsai et al.: Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. In: Blood. 114. Jahrgang, Nr.24, 2009, S.4928–4932, doi:10.1182/blood-2009-08-237651, PMID 19828698.
N. van de Donk et al.: The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. In: Haematologica. 99. Jahrgang, Nr.6, 21. März 2014, S.984–96, doi:10.3324/haematol.2013.100552, PMID 23224402, PMC 4040895 (freier Volltext).
N Leung et al.: Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. In: Blood. 120. Jahrgang, Nr.22, 22. November 2012, S.4292–4295, doi:10.1182/blood-2012-07-445304, PMID 23224402.
O. Landgren et al.: Shall we treat smoldering multiple myeloma in the near future? In: Hematology Am Soc Hematol Educ Program. 2017. Jahrgang, Nr.1, 2017, S.194–204, doi:10.1182/asheducation-2017.1.194, PMID 29222256.
A. Nerlich, H. Rohrbach, A. Zink: Paläopathologie altägyptischer Mumien und Skelette. In: Pathologe. 23, 2002, S. 379, doi:10.1007/s00292-002-0558-9
R. A. Kyle et al.: Review of 1027 patients with newly diagnosed multiple myeloma. In: Mayo Clin Proc. 78. Jahrgang, Nr.1, 2003, S.21–33, doi:10.4065/78.1.21, PMID 12528874.
M. Drayson et al.: Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. In: Blood. 108. Jahrgang, Nr.6, 2006, S.2013-9, doi:10.1182/blood-2006-03-008953, PMID 16728700.
M. M. Dupuis et al.: Non-secretory multiple myeloma: from biology to clinical management. In: Onco Targets Ther. 9. Jahrgang, 2004, S.7583–7590, doi:10.2147/OTT.S122241, PMID 28008276, PMC 5171196 (freier Volltext).
A.M. Rajan et al.: Interpretation of cytogenetic results in multiple myeloma for clinical practice. In: Blood Cancer J. 5. Jahrgang, Nr.10, 30. Oktober 2015, S.e365, doi:10.1038/bcj.2015.92, PMID 26517360, PMC 4635200 (freier Volltext).
T Golombick et al.: Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures. In: Acta Haematol. 120. Jahrgang, Nr.2, 14. Oktober 2008, S.87–90, doi:10.1159/000162282, PMID 18852483.
N Steiner et al.: Are neurological complications of monoclonal gammopathy of undetermined significance underestimated? In: Oncotarget. 8. Jahrgang, Nr.3, 10. Dezember 2016, S.5081–5091, doi:10.18632/oncotarget.13861, PMID 27974705, PMC 5354894 (freier Volltext).
SV Rajkumar et al.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. In: Lancet Oncology. 15. Jahrgang, November 2014, S.e538–e548, doi:10.1038/leu.2010.60, PMID 20410922.
S. K. Kumar u. a.: Improved survival in multiple myeloma and the impact of novel therapies. In: Blood. Nr.111(5), März 2008, S.2516–2520, doi:10.1182/blood-2007-10-116129.
Philip R. Greipp, Jesus San Miguel, Brian G.M. Durie, John J. Crowley, Bart Barlogie: International Staging System for Multiple Myeloma. In: Journal of Clinical Oncology. Band23, Nr.15, 20. Mai 2005, ISSN0732-183X, S.3412–3420, doi:10.1200/JCO.2005.04.242.
A. Palumbo et al.: Revised International Staging System for Multiple Myeloma: a report from IMWG. In: J Clin Oncol. 33. Jahrgang, Nr.26, 10. September 2015, S.2863–2869, doi:10.1200/JCO.2015.61.2267, PMID 26240224, PMC 4846284 (freier Volltext).
R. A. Kyle et al.: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma:IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. In: Leukemia. 24. Jahrgang, 4. Februar 2010, S.1121–1127, doi:10.1038/leu.2010.60, PMID 20410922.
R. S. Go et al.: Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. In: Leukemia. 15. Jahrgang, Nr.3, 28. September 2014, S.177–186.e4, doi:10.1016/j.clml.2014.09.004, PMID 25445471, PMC 4344843 (freier Volltext).
P. Moreau: The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies. In: Seminars in Hematology. Nr.49(1), Juli 2012, S.33–46, doi:10.1053/j.seminhematol.2012.05.004.
Arghya Ray, Durgadevi Ravillah, Deepika S. Das, Yan Song, Eva Nordström, Joachim Gullbo, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson: A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. In: British Journal of Haematology. Band174, Nr.3, August 2016, S.397–409, doi:10.1111/bjh.14065, PMID 27098276, PMC 4961600 (freier Volltext) – (wiley.com [abgerufen am 10. Mai 2023]).
Vanessa Piechotta, Tina Jakob, Peter Langer, Ina Monsef, Christof Scheid: Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. In: Cochrane Database of Systematic Reviews. 25. November 2019, doi:10.1002/14651858.CD013487 (wiley.com [abgerufen am 9. Juli 2020]).
Sheila A Fisher, Antony Cutler, Carolyn Doree, Susan J Brunskill, Simon J Stanworth: Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. In: Cochrane Database of Systematic Reviews. 30. Januar 2019, doi:10.1002/14651858.CD009768.pub2 (wiley.com [abgerufen am 9. Juli 2020]).
V. Kotla et al.: Mechanism of action of lenalidomide in hematological malignancies. In: J Hematol Oncol. 12. Jahrgang, Nr.2, 12. August 2009, S.36, doi:10.1186/1756-8722-2-36, PMID 19674465, PMC 2736171 (freier Volltext).
H. M. Lokhorst et al.: Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. In: The New England Journal of Medicine. 373. Jahrgang, Nr.13, 24. September 2015, S.1207–1219, doi:10.1056/NEJMoa1506348, PMID 26308596.
Linus Knips, Nils Bergenthal, Fiona Streckmann, Ina Monsef, Thomas Elter: Aerobic physical exercise for adult patients with haematological malignancies. In: Cochrane Database of Systematic Reviews. 31. Januar 2019, doi:10.1002/14651858.CD009075.pub3 (wiley.com [abgerufen am 9. Juli 2020]).
S. Kumar et al.: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. In: Lancet Oncol. 17. Jahrgang, Nr.8, 2016, S.e328–e346, doi:10.1016/s1470-2045(16)30206-6, PMID 27511158.
F. E. Davies: Is molecular remission the goal of multiple myeloma therapy? In: Hematology Am Soc Hematol Educ Program. 2017. Jahrgang, Nr.1, 2017, S.205–211, doi:10.1182/asheducation-2017.1.205, PMID 29222257.
H. Ludwig et al.: Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. In: Leukemia. 27. Jahrgang, Nr.2, 2013, S.213–219, doi:10.1038/leu.2012.197, PMID 22955329.
M. Michallet et al.: Heavy + light chain monitoring correlates with clinical outcome in multiple myeloma patients. In: Leukemia. 32. Jahrgang, Nr.2, 2017, S.376–382, doi:10.1038/leu.2017.209, PMID 28663581.
N. C. Munshi: Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. In: JAMA Oncol. 3. Jahrgang, Nr.1, 2017, S.28–35, doi:10.1001/jamaoncol.2016.3160, PMID 27632282.
europa.eu
ema.europa.eu
EMA: Pepaxti. 21. Juni 2022, abgerufen am 10. Mai 2023 (englisch).
Oswald Panagl: Das Suffix -om (= griech. -ωμα) — ein Pseudo-Lexem der medizinischen Terminologie. In: Glotta. Band 49, Heft 1/2, 1971, S. 42–45. JSTOR:40266190.
Oswald Panagl: Das Suffix -om (= griech. -ωμα) — ein Pseudo-Lexem der medizinischen Terminologie. In: Glotta. Band 49, Heft 1/2, 1971, S. 44. JSTOR:40266190.
M. Dimopoulos et al.: Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. In: N Engl J Med. Nr.357, 2007, S.2123–2132 (Abstract).
nih.gov
ncbi.nlm.nih.gov
O. Landgren et al.: Monoclonal gammopathy of undetermined significance (mgus) consistently precedes multiple myeloma: a prospective study. In: Blood. 113. Jahrgang, Nr.22, 2009, S.5412–5417, doi:10.1182/blood-2008-12-194241, PMID 19179464.
H. T. Tsai et al.: Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. In: Blood. 114. Jahrgang, Nr.24, 2009, S.4928–4932, doi:10.1182/blood-2009-08-237651, PMID 19828698.
N. van de Donk et al.: The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. In: Haematologica. 99. Jahrgang, Nr.6, 21. März 2014, S.984–96, doi:10.3324/haematol.2013.100552, PMID 23224402, PMC 4040895 (freier Volltext).
N Leung et al.: Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. In: Blood. 120. Jahrgang, Nr.22, 22. November 2012, S.4292–4295, doi:10.1182/blood-2012-07-445304, PMID 23224402.
O. Landgren et al.: Shall we treat smoldering multiple myeloma in the near future? In: Hematology Am Soc Hematol Educ Program. 2017. Jahrgang, Nr.1, 2017, S.194–204, doi:10.1182/asheducation-2017.1.194, PMID 29222256.
D. Morse, R. C. Dailey, J. Bunn: Prehistoric multiple myeloma. In: Bulletin of the New York Academy of Medicine. Nr.50, 1974, S.447–458, PMID 4594853.
R. A. Kyle: Multiple myeloma: an odyssey of discovery. In: British Journal of Haematology. Nr.111(4), 2000, S.1035–1044, PMID 11167737.
S. C. Bernstein, A. R. Perez-Atayde, H. J. Weinstein: Multiple myeloma in a child. In: Cancer. Band 56, Nr. 8, Oktober 1985, S. 2143–2147. PMID 3928137.
R. A. Kyle et al.: Review of 1027 patients with newly diagnosed multiple myeloma. In: Mayo Clin Proc. 78. Jahrgang, Nr.1, 2003, S.21–33, doi:10.4065/78.1.21, PMID 12528874.
M. Drayson et al.: Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. In: Blood. 108. Jahrgang, Nr.6, 2006, S.2013-9, doi:10.1182/blood-2006-03-008953, PMID 16728700.
M. M. Dupuis et al.: Non-secretory multiple myeloma: from biology to clinical management. In: Onco Targets Ther. 9. Jahrgang, 2004, S.7583–7590, doi:10.2147/OTT.S122241, PMID 28008276, PMC 5171196 (freier Volltext).
A.M. Rajan et al.: Interpretation of cytogenetic results in multiple myeloma for clinical practice. In: Blood Cancer J. 5. Jahrgang, Nr.10, 30. Oktober 2015, S.e365, doi:10.1038/bcj.2015.92, PMID 26517360, PMC 4635200 (freier Volltext).
T Golombick et al.: Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures. In: Acta Haematol. 120. Jahrgang, Nr.2, 14. Oktober 2008, S.87–90, doi:10.1159/000162282, PMID 18852483.
N Steiner et al.: Are neurological complications of monoclonal gammopathy of undetermined significance underestimated? In: Oncotarget. 8. Jahrgang, Nr.3, 10. Dezember 2016, S.5081–5091, doi:10.18632/oncotarget.13861, PMID 27974705, PMC 5354894 (freier Volltext).
SV Rajkumar et al.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. In: Lancet Oncology. 15. Jahrgang, November 2014, S.e538–e548, doi:10.1038/leu.2010.60, PMID 20410922.
B. G. Durie et al.: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. In: Cancer. 36. Jahrgang, Nr.3, September 1975, S.842–854, PMID 1182674.
A. Palumbo et al.: Revised International Staging System for Multiple Myeloma: a report from IMWG. In: J Clin Oncol. 33. Jahrgang, Nr.26, 10. September 2015, S.2863–2869, doi:10.1200/JCO.2015.61.2267, PMID 26240224, PMC 4846284 (freier Volltext).
R. A. Kyle et al.: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma:IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. In: Leukemia. 24. Jahrgang, 4. Februar 2010, S.1121–1127, doi:10.1038/leu.2010.60, PMID 20410922.
R. S. Go et al.: Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. In: Leukemia. 15. Jahrgang, Nr.3, 28. September 2014, S.177–186.e4, doi:10.1016/j.clml.2014.09.004, PMID 25445471, PMC 4344843 (freier Volltext).
Arghya Ray, Durgadevi Ravillah, Deepika S. Das, Yan Song, Eva Nordström, Joachim Gullbo, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson: A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. In: British Journal of Haematology. Band174, Nr.3, August 2016, S.397–409, doi:10.1111/bjh.14065, PMID 27098276, PMC 4961600 (freier Volltext) – (wiley.com [abgerufen am 10. Mai 2023]).
V. Kotla et al.: Mechanism of action of lenalidomide in hematological malignancies. In: J Hematol Oncol. 12. Jahrgang, Nr.2, 12. August 2009, S.36, doi:10.1186/1756-8722-2-36, PMID 19674465, PMC 2736171 (freier Volltext).
H. M. Lokhorst et al.: Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. In: The New England Journal of Medicine. 373. Jahrgang, Nr.13, 24. September 2015, S.1207–1219, doi:10.1056/NEJMoa1506348, PMID 26308596.
S. Kumar et al.: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. In: Lancet Oncol. 17. Jahrgang, Nr.8, 2016, S.e328–e346, doi:10.1016/s1470-2045(16)30206-6, PMID 27511158.
F. E. Davies: Is molecular remission the goal of multiple myeloma therapy? In: Hematology Am Soc Hematol Educ Program. 2017. Jahrgang, Nr.1, 2017, S.205–211, doi:10.1182/asheducation-2017.1.205, PMID 29222257.
H. Ludwig et al.: Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. In: Leukemia. 27. Jahrgang, Nr.2, 2013, S.213–219, doi:10.1038/leu.2012.197, PMID 22955329.
M. Michallet et al.: Heavy + light chain monitoring correlates with clinical outcome in multiple myeloma patients. In: Leukemia. 32. Jahrgang, Nr.2, 2017, S.376–382, doi:10.1038/leu.2017.209, PMID 28663581.
N. C. Munshi: Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. In: JAMA Oncol. 3. Jahrgang, Nr.1, 2017, S.28–35, doi:10.1001/jamaoncol.2016.3160, PMID 27632282.
Vanessa Piechotta, Tina Jakob, Peter Langer, Ina Monsef, Christof Scheid: Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. In: Cochrane Database of Systematic Reviews. 25. November 2019, doi:10.1002/14651858.CD013487 (wiley.com [abgerufen am 9. Juli 2020]).
Sheila A Fisher, Antony Cutler, Carolyn Doree, Susan J Brunskill, Simon J Stanworth: Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. In: Cochrane Database of Systematic Reviews. 30. Januar 2019, doi:10.1002/14651858.CD009768.pub2 (wiley.com [abgerufen am 9. Juli 2020]).
Linus Knips, Nils Bergenthal, Fiona Streckmann, Ina Monsef, Thomas Elter: Aerobic physical exercise for adult patients with haematological malignancies. In: Cochrane Database of Systematic Reviews. 31. Januar 2019, doi:10.1002/14651858.CD009075.pub3 (wiley.com [abgerufen am 9. Juli 2020]).
onlinelibrary.wiley.com
Arghya Ray, Durgadevi Ravillah, Deepika S. Das, Yan Song, Eva Nordström, Joachim Gullbo, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson: A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. In: British Journal of Haematology. Band174, Nr.3, August 2016, S.397–409, doi:10.1111/bjh.14065, PMID 27098276, PMC 4961600 (freier Volltext) – (wiley.com [abgerufen am 10. Mai 2023]).
zdb-katalog.de
Philip R. Greipp, Jesus San Miguel, Brian G.M. Durie, John J. Crowley, Bart Barlogie: International Staging System for Multiple Myeloma. In: Journal of Clinical Oncology. Band23, Nr.15, 20. Mai 2005, ISSN0732-183X, S.3412–3420, doi:10.1200/JCO.2005.04.242.